Evaluation of the effectiveness of trehalose on autism

Evaluation of the effectiveness of trehalose augmentation on children with autism spectrum disorder (ASD)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181022041407N11

Enrollment

Registered

2024-09-26

Start date

2024-10-22

Completion date

Unknown

Last updated

2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism spectrum disorder (ASD). Childhood autism

Interventions

Intervention 1: Intervention group: 10 g Trehalose per day for 12 weeks made by Shaanxi Fruiterco Biotechnology Co.,Ltd. Intervention 2: Control group: Placebo (containing Sucrose) for 12 weeks.

Eligibility

Sex/Gender

All

Age

5 Years to 15 Years

Inclusion criteria

Inclusion criteria: Suffering from autism spectrum disorder (ASD) according to DSM criteria Age 5-15 years IQ more than 70 and not suffering from intellectual disability Having a Persian literate parent to complete the questionnaires Informed consent from the parents or his legal guardian Lack of other psychiatric illnesses

Exclusion criteria

Exclusion criteria: Not use the administered treatment Not willingness to continue the research project

Design outcomes

Primary

Measure	Time frame
Scale of autism. Timepoint: Baseline, after 6 weeks, after 12 weeks. Method of measurement: Childhood Autism Rating Scale (CARS).;Assessment the severity and improvement of autism. Timepoint: Baseline, after 6 weeks, after 12 weeks. Method of measurement: Clinical Global Impression (CGI) questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Emadzadeh

Mashhad University of Medical Sciences

maryamemadzadeh@yahoo.com+98 51 3841 7403

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026